
    
      Patients with gastric cancer who are also inactive hepatitis B carriers are enrolled and
      randomized into two groups as following. Patients in experimental group are treated with
      entecavir prophylactically in the dose of 0.5mg p.o. every day from the initiation of
      chemotherapy till 6 months after the end of chemotherapy.Patients in active comparator group
      are only treated with entecavir in the dose of 0.5mg p.o. every day from the time that the
      DNA copies of hepatitis B virus are more than 100 IU/ml till 6 months after the end of
      chemotherapy.
    
  